A Phase 1/2a Open-label Trial to Evaluate the Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207, a PSMA-targeting Bispecific γδ-T Cell Engager, Alone or With Low Dose Interleukin-2 or Pembrolizumab, in Patients With Therapy Refractory mCRPC
Latest Information Update: 23 Aug 2024
At a glance
- Drugs LAVA-1207 (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man
- Acronyms KEYNOTE-F73
- Sponsors Lava Therapeutics
- 20 Aug 2024 According to a Lava Therapeutics media release, initiated dosing in the LAVA-1207 plus pembrolizumab dose-escalation arm (KEYNOTE-F73) to potentially enhance the anti-tumor activity of LAVA-1207. This arm also utilizes the established step-dosing regimen.
- 20 Aug 2024 According to a Lava Therapeutics media release, this trial is nnrolling in dose level 12 with no greater than Grade 2 Cytokine Release Syndrome (CRS) since the implementation of step-dosing in Q1 2024. Next data update for LAVA-1207 program expected in Q4 2024.
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.